Momenta Pharmaceuticals Inc., of Cambridge, Mass., said underwriters UBS Investment Bank, Cowen & Co. and Canaccord Genuity exercised their overallotment option related to the biotech's recent public stock offering, purchasing an additional 218,647 shares for $14.35 each in addition to the 4 million shares already sold.